Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis
Open accessThe DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Abstract
Introduction: Gut microbiota can significantly affect the effectiveness of immune checkpoint inhibitors (ICIs) in cancer patients. Recently, antibiotics were shown to decrease survival rate of patients treated by ICIs. Proton pump inhibitors (PPIs) can indeed modulate microbiota’s diversity, therefore altering ICIs response. A meta-analysis was performed based on published data to verify this hypothesis. Methods: In this study, over 41 publications, exploring the impact of concomitant PPI treatment on outcomes of ICI-treated patients, were analyzed. Evaluated endpoints were overall survival (OS) and progression-free survival (PFS). Pooled hazard ratios (HRs) with a 95% confidence interval (CI) were reported in ICIs in PPI users versus non-PPI users. Subgroup analyses were performed to minimize the impact of study heterogeneity and to investigate the influence of PPI on the different groups of interest. There was no evidence of publication bias for OS and PFS analysis in subgroup analysis. Results: Forty-one studies were included in the meta-analysis, including a total of 20,042 patients. OS of patients receiving ICIs was negatively correlated in patients concomitantly treated with PPI (HR=1.37; 95%CI, 1.23–1.52). PFS of cancer patients receiving ICIs was also negatively correlated with PPI treatment (HR=1.28; 95%CI, 1.15–1.42). PPI and ICI use was associated with worst OS and PFS not only for non-small-cell lung cancer (NSCLC) or urothelial cancer patients but also for patients treated with anti PD-1 (OS) and anti PD-L1 (OS and PFS) immunotherapies when administered in non-first line and when PPI was received as baseline treatment or in 60 days before ICI initiation. PPI and ICI use also showed the worst OS and PFS for patients from Europe and Asia. Conclusion: This meta-analysis suggests that PPI treatment leads to significantly worse outcomes in advanced cancer patients treated by ICIs in terms of PFS and OS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Another meta-analysis showed that PPIs—which also affect gut bacterial diversity—can similarly have a negative influence on ICB therapeutic outcomes (Lopes et al., 2023).”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Lopes et al., 2023
The cited source says what the claim attributes to it.
In the citing paper
“Therefore, gut microbial dysbiosis - which can be caused by comedications such as antibiotics (Elkrief et al., 2024b) and proton pump inhibitors (PPIs) (Lopes et al., 2023), the malignancy itself (Yonekura et al., 2022), lifestyle factors (e.g., diet and exercise), and age (Thomas et al., 2023; Zhernakova et al., 2016) - can significantly impair the effectiveness of immunotherapies.”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Lopes et al., 2023
In the citing paper
“Another meta-analysis that examined 41 studies and 20,000 patients similarly demonstrated the negative impact of PPI treatment on patients treated with ICIs.105”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · cited 5×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
BackgroundInfluentialRole of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385 · cited 1×
“In fact, ICI responses are closely related to the gut microbiome composition (14) because bacteria types or bacteria metabolites modulate the antitumor immunity and inflammation (15).”
BackgroundMetabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J. R., Pfeffer, K., Coffer, P. J., et al. (2013) · Nature · doi:10.1038/nature12726 · Cited by 4,838 · cited 6×
“Tomizaki (55) 2022 40 Asia 30 (75) 72 NA Urothelial carcinoma”
BackgroundInfluentialGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 3×
“In fact, ICI responses are closely related to the gut microbiome composition (14) because bacteria types or bacteria metabolites modulate the antitumor immunity and inflammation (15).”
BackgroundAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 8×
“Median age ECOG PS 0- 1/2 Cancer type ICI treatment Treatment line ICI mon apy or atio Giordan (28) 2021 212 Europe 143 (68) 64 161/50 Multiple Nivolumab, pembrolizumab, ipilimumab First, second, or beyond Monother associatio Hakozaki (29) 2018 90 Asia 57 (63,3) 67 64/26 NSCLC Nivolumab Second or beyond Monother Homic…”
BackgroundInfluentialGut microbiota, metabolites and host immunity
Rooks, M. G., & Garrett, W. S. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.42 · Cited by 3,409 · cited 3×
“Routy (47) 2017 249 Europe 177 (71,1) 63 NA Multiple Anti-PD-1, anti-PD-L1, anti-CTLA-4 First, second, or beyond Monothera association”
BackgroundThe commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107 · cited 2×
“Chalabi (10) 2020 757 America/ Europe 471 (62,2) NA 755/NA NSCLC Atezolizumab Second or beyond M”
BackgroundResultThe Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050 · cited 3×
“fragilis, which activated Th1 cells and cross-reactivity between bacterial antigens and tumor antigens (68).”
BackgroundProton pump inhibitors affect the gut microbiome
Imhann, F., Bonder, M. J., Vich Vila, A., Fu, J., Mujagic, Z., Vork, L., Tigchelaar, E. F., Jankipersadsing, S. A., Cenit, M. C., Harmsen, H. J. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310376 · Cited by 1,371 · cited 2×
“On the contrary, the population of bacteria associated with resistance to ICIs, such as Bacteroidetes (79) and Escherichia coli (76, 77), increased with PPI treatment.”
BackgroundBalar, A. V., Castellano, D., O'Donnell, P. H., Grivas, P., Vuky, J., Powles, T., Plimack, E. R., Hahn, N. M., de Wit, R., Pang, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30616-2 · Cited by 1,333
Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310
Gadgeel, S., Rodríguez-Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., Hui, R., Hochmair, M. J., Clingan, P., Powell, S. F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03136 · Cited by 1,116
Arbour, K. C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., Martínez-Bernal, G., Ferrara, R., Lai, W. V., Hendriks, L. E. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.0006 · Cited by 1,071 · cited 4×
“Peng (44) 2022 233 America 130 (55,8) 64 186/47 Multiple Nivolumab, pembrolizumab, and ipilimumab First, second, or beyond Monothera association”
BackgroundInfluentialProton pump inhibitors alter the composition of the gut microbiota
Jackson, M. A., Goodrich, J. K., Maxan, M.-E., Freedberg, D. E., Abrams, J. A., Poole, A. C., Sutter, J. L., Welter, D., Ley, R. E., Bell, J. T., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310861 · Cited by 895 · cited 3×
“RuizBanobre (48) 2021 119 Europe 96 (81) 69 99/20 Urothelial carcinoma Atezolizumab, pembrolizumab, nivolumab, durvalumab First, second, or beyond Monothera”
BackgroundImpact of commonly used drugs on the composition and metabolic function of the gut microbiota
Vich Vila, A., Collij, V., Sanna, S., Sinha, T., Imhann, F., Bourgonje, A. R., Mujagic, Z., Jonkers, D. M. A. E., Masclee, A. A. M., Fu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14177-z · Cited by 791
Frankel, A. E., Coughlin, L. A., Kim, J., Froehlich, T. W., Xie, Y., Frenkel, E. P., & Koh, A. Y. (2017) · Neoplasia · doi:10.1016/j.neo.2017.08.004 · Cited by 709 · cited 3×
“Nguyen (42) 2019 95 Asia 62 (65,3) 68 NA Multiple Nivolumab NA Monothera”
BackgroundDerosa, L., Routy, B., Thomas, A. M., Iebba, V., Zalcman, G., Friard, S., Mazieres, J., Audigier-Valette, C., Moro-Sibilot, D., Goldwasser, F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01655-5 · Cited by 685 · cited 4×
“5 months when absent from the gastrointestinal tract) (63).”
BackgroundInfluentialMcQuade, J. L., Daniel, C. R., Hess, K. R., Mak, C., Wang, D. Y., Rai, R. R., Park, J. J., Haydu, L. E., Spencer, C., Wongchenko, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30078-0 · Cited by 664
Paulos, C. M., Wrzesinski, C., Kaiser, Hinrichs, C. S., Chieppa, M., Cassard, L., Palmer, D. C., Boni, A., Muranski, P., Yu, Z., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32205 · Cited by 586 · cited 1×
“For example, lipopolysaccharides (LPS) improve adoptive T-cell activity (69), and bacterial DNAs”
BackgroundOverprescribing proton pump inhibitors
Forgacs, I., & Loganayagam, A. (2008) · BMJ · doi:10.1136/bmj.39406.449456.be · Cited by 553
Hall, J. A., Bouladoux, N., Sun, C. M., Wohlfert, E. A., Blank, R. B., Zhu, Q., Grigg, M. E., Berzofsky, J. A., & Belkaid, Y. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.009 · Cited by 494 · cited 4×
“Okuyama (43) 2022 155 Asia 109 (70,3) 72 121/34 Urothelial carcinoma Pembrolizumab, nivolumab, atezolizumab, and durvalumab Second or beyond NA”
BackgroundInfluentialCortellini, A., Bersanelli, M., Buti, S., Cannita, K., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Michiara, M., Di Marino, P., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0527-y · Cited by 413
Kichenadasse, G., Miners, J. O., Mangoni, A. A., Rowland, A., Hopkins, A. M., & Sorich, M. J. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5241 · Cited by 339 · cited 2×
“First, obesity may cause low systemic inflammation and impaired immune response, which could induce exhausted T-cell (which expressed PD-1) and lymphocytes dysfunction (85).”
BackgroundExploring the emerging role of the microbiome in cancer immunotherapy
Fessler, J., Matson, V., & Gajewski, T. F. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0574-4 · Cited by 319 · cited 1×
“Several studies showed that intestinal microbiota had a significant impact on immune system and ICI responses (61).”
BackgroundChalabi, M., Cardona, A., Nagarkar, D. R., Dhawahir Scala, A., Gandara, D. R., Rittmeyer, A., Albert, M. L., Powles, T., Kok, M., & Herrera, F. G. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.006 · Cited by 294 · cited 3×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
BackgroundIraporda, C., Errea, A., Romanin, D. E., Cayet, D., Pereyra, E., Pignataro, O., Sirard, J. C., Garrote, G. L., Abraham, A. G., & Rumbo, M. (2015) · Immunobiology · doi:10.1016/j.imbio.2015.06.004 · Cited by 282 · cited 3×
“Fukuokaya (26) 2022 227 Asia 165 (72,7) 70 NA Urothelial carcinoma Pembrolizumab Second or beyond M”
BackgroundCortellini, A., Tucci, M., Adamo, V., Stucci, L. S., Russo, A., Tanda, E. T., Spagnolo, F., Rastelli, F., Bisonni, R., Santini, D., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001361 · Cited by 275 · cited 2×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified
Bruno, G., Zaccari, P., Rocco, G., Scalese, G., Panetta, C., Porowska, B., Pontone, S., & Severi, C. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i22.2706 · Cited by 258 · cited 3×
“On the contrary, the population of bacteria associated with resistance to ICIs, such as Bacteroidetes (79) and Escherichia coli (76, 77), increased with PPI treatment.”
BackgroundSide Effects of Long‐Term Proton Pump Inhibitor Use: A Review
Haastrup, P. F., Thompson, W., Søndergaard, J., & Jarbøl, D. E. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13023 · Cited by 230
McDermott, D., Haanen, J., Chen, T.-T., Lorigan, P., & O'Day, S. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt291 · Cited by 219
Fucà, G., Galli, G., Poggi, M., Lo Russo, G., Proto, C., Imbimbo, M., Ferrara, R., Zilembo, N., Ganzinelli, M., Sica, A., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000457 · Cited by 209 · cited 3×
“Hopkins (32) 2021 1,202 Worldwide 720 (59,9) 63 1,202/0 NSCLC Atezolizumab First Associatio”
BackgroundCortellini, A., Maïo, M. D., Nigro, O., Leonetti, A., Cortinovis, D. L., Aerts, J. G. J. V., Guaitoli, G., Barbieri, F., Giusti, R., Ferrara, M. G., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002421 · Cited by 172 · cited 2×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
Zhao, S., Gao, G., Li, W., Li, X., Zhao, C., Jiang, T., Jia, Y., He, Y., Li, A., Su, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.017 · Cited by 164 · cited 3×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
BackgroundGurav, A., Sivaprakasam, S., Bhutia, Y. D., Boettger, T., Singh, N., & Ganapathy, V. (2015) · Biochemical Journal · doi:10.1042/bj20150242 · Cited by 164 · cited 1×
“For example, short-chain fatty acids were shown to impact cytokines production, DC function (72, 73), and Bcell class switching and to facilitate Treg differentiation (74, 75).”
BackgroundUse of proton pump inhibitors in adults in France: a nationwide drug utilization study
Lassalle, M., Tri, T. L., Bardou, M., Biour, M., Kirchgesner, J., Rouby, F., Dumarcet, N., Zureik, M., & Dray‐Spira, R. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02810-1 · Cited by 142
Farrell, B., Pottie, K., Rojas-Fernandez, C. H., Bjerre, L. M., Thompson, W., & Welch, V. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161248 · Cited by 134 · cited 1×
“PPI deprescription should be conducted whenever possible, following deprescribing protocols (86, 87).”
BackgroundWhite, C. A., Pone, E. J., Lam, T., Tat, C., Hayama, K. L., Li, G., Zan, H., & Casali, P. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401702 · Cited by 129 · cited 2×
“For example, short-chain fatty acids were shown to impact cytokines production, DC function (72, 73), and Bcell class switching and to facilitate Treg differentiation (74, 75).”
BackgroundImpact of prior antibiotic use on the efficacy of nivolumab for non‑small cell lung cancer
Hakozaki, T., Okuma, Y., Omori, M., & Hosomi, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.9899 · Cited by 115 · cited 2×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
BackgroundButi, S., Bersanelli, M., Perrone, F., Tiseo, M., Tucci, M., Adamo, V., Stucci, L. S., Russo, A., Tanda, E. T., Spagnolo, F., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2020.09.033 · Cited by 115 · cited 2×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
Kostine, M., Mauric, E., Tison, A., Barnetche, T., Barre, A., Nikolski, M., Rouxel, L., Dutriaux, C., Dousset, L., Prey, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.036 · Cited by 101
Tomita, Y., Goto, Y., Sakata, S., Imamura, K., Minemura, A., Oka, K., Hayashi, A., Jodai, T., Akaike, K., Anai, M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2081010 · Cited by 100 · cited 3×
“Tomita (54) 2022 118 Asia 99 (83,8) 68 52/20 NSCLC”
BackgroundIglesias-Santamaría, A. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02282-w · Cited by 90 · cited 2×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab
Hopkins, A. M., Kichenadasse, G., Karapetis, C. S., Rowland, A., & Sorich, M. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1876 · Cited by 88 · cited 2×
“Hopkins (31) 2020 1,360 America/ Europe NA 68 1,336/24 Urothelial carcinoma Atezolizumab First, second Monother”
BackgroundSVATON, M., ZEMANOVA, M., ZEMANOVA, P., KULTAN, J., FISCHER, O., SKRICKOVA, J., JAKUBIKOVA, L., CERNOVSKA, M., HRNCIARIK, M., JIROUSEK, M., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14182 · Cited by 88 · cited 2×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
Giordan, Q., Salleron, J., Vallance, C., Moriana, C., & Clément-Duchêne, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.716317 · Cited by 84 · cited 2×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
BackgroundMollica, V., Santoni, M., Matrana, M. R., Basso, U., Giorgi, U. D., Rizzo, A., Maruzzo, M., Marchetti, A., Rosellini, M., Bleve, S., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00861-y · Cited by 82 · cited 2×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
BackgroundLee, J. H., Hyung, S., Lee, J., & Choi, S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005226 · Cited by 82
Hopkins, A. M., Kichenadasse, G., McKinnon, R. A., Abuhelwa, A. Y., Logan, J. M., Badaoui, S., Karapetis, C. S., Rowland, A., & Sorich, M. J. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01606-4 · Cited by 81
Kim, H., Lee, J. E., Hong, S. H., Lee, M. A., Kang, J. H., & Kim, I.-H. (2019) · BMC Cancer · doi:10.1186/s12885-019-6267-z · Cited by 72
Stein, C., Burtey, S., Mancini, J., Pelletier, M., Sallée, M., Brunet, P., Berbis, P., Grob, J., Honoré, S., Gaudy‐Marqueste, C., et al. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa137 · Cited by 69
Sen, S., Carmagnani Pestana, R., Hess, K., Viola, G. M., & Subbiah, V. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy453 · Cited by 65
Spakowicz, D., Hoyd, R., Muniak, M., Husain, M., Bassett, J. S., Wang, L., Tinoco, G., Patel, S. H., Burkart, J., Miah, A., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06882-6 · Cited by 62 · cited 2×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
Miura, K., Sano, Y., Niho, S., Kawasumi, K., Mochizuki, N., Yoh, K., Matsumoto, S., Zenke, Y., Ikeda, T., Nosaki, K., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14001 · Cited by 62
Failing, J. J., Finnes, H. D., Kottschade, L. A., Allred, J. B., & Markovic, S. N. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000299 · Cited by 62 · cited 4×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
BackgroundInfluentialBañobre, J. R., Díaz, A. M., Calvo, O. F., Núñez, N. F., Medina, A., Santomé, L., Lázaro-Quintela, M., Mateos-González, M., Cid, N. G., López‐López, R., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100090 · Cited by 53
Gaucher, L., Adda, L., Séjourné, A., Joachim, C., Chaby, G., Poulet, C., Liabeuf, S., Gras‐Champel, V., Masmoudi, K., Houessinon, A., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211000591 · Cited by 53 · cited 2×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
Chen, B., Chen, Y., Dragomir, M. P., Chi, D., Chen, W., Horst, D. A., Călin, G. A., & Li, Q. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221111703 · Cited by 45
Li, C., Xia, Z., Li, A., & Meng, J. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-7498 · Cited by 41
Baek, Y., Kang, E. J., Hong, S., Park, S., Kim, J. H., & Shin, J. (2021) · International Journal of Cancer · doi:10.1002/ijc.33892 · Cited by 41 · cited 2×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
BackgroundPeng, K., Chen, K., Teply, B. A., Yee, G. C., Farazi, P. A., & Lyden, E. R. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280211033938 · Cited by 40 · cited 2×
“Peng (44) 2022 233 America 130 (55,8) 64 186/47 Multiple Nivolumab, pembrolizumab, and ipilimumab First, second, or beyond Monothera association”
BackgroundLi, M., Zeng, C., Yao, J., Ge, Y., & An, G. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106972 · Cited by 36 · cited 1×
“Two other metaanalyses showed no association between PPI consumption and survival outcomes in ICI patients (n=1,167 patients, five publications and 1,392 patients, seven studies, respectively) (59, 60), FIGURE 1”
BackgroundSands, S. A., Tsau, S., Yankee, T. M., Parker, B. L., Ericsson, A. C., & LeVine, S. M. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-605 · Cited by 30 · cited 4×
“On the contrary, the population of bacteria associated with resistance to ICIs, such as Bacteroidetes (79) and Escherichia coli (76, 77), increased with PPI treatment.”
BackgroundInfluentialFukuokaya, W., Kimura, T., Komura, K., Uchimoto, T., Nishimura, K., Yanagisawa, T., Imai, Y., Iwatani, K., Ito, K., Urabe, F., et al. (2022) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2022.02.020 · Cited by 28
Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma
Okuyama, Y., Hatakeyama, S., Numakura, K., Narita, T., Tanaka, T. D., Miura, Y., Sasaki, D., Noro, D., Tokui, N., Okamoto, T., et al. (2021) · BJUI Compass · doi:10.1002/bco2.118 · Cited by 26 · cited 2×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
BackgroundAntacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma
Jun, T. W., Özbek, U., Dharmapuri, S., Hardy-Abeloos, C., Zhu, H., Lin, J.-Y., Personeni, N., Pressiani, T., Nishida, N., Lee, P., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211010937 · Cited by 26 · cited 2×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
BackgroundDeng, R., Zhang, H., Li, Y., & Shi, Y. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000442 · Cited by 24
Conde‐Estévez, D., Monge‐Escartín, I., Ríos-Hoyo, A., Monzonís, X., Echeverría-Esnal, D., Moliner, L., Durán, X., Taus, Á., & Arriola, E. (2020) · Journal of Chemotherapy · doi:10.1080/1120009x.2020.1849488 · Cited by 22 · cited 2×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
BackgroundObesity, Akkermansia muciniphila, and Proton Pump Inhibitors: Is there a Link?
Davis, J. A., Collier, F., Mohebbi, M., Stuart, A. L., Loughman, A., Pasco, J. A., & Jacka, F. N. (2020) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2020.10.006 · Cited by 21 · cited 2×
“More specifically, the population of bacteria associated with response to ICIs, including Bifidobacterium sp (76–78), Ruminococcaceae (76–78), Akkermansia muciniphila (79, 80), and Alistipes sp (77), were found to be decreased by PPI treatment.”
BackgroundTomisaki, I., Harada, M., Minato, A., Nagata, Y., Kimuro, R., Higashijima, K., Harada, K., & Fujimoto, N. (2022) · Anticancer Research · doi:10.21873/anticanres.15638 · Cited by 21 · cited 3×
“Peng (44) 2022 233 America 130 (55,8) 64 186/47 Multiple Nivolumab, pembrolizumab, and ipilimumab First, second, or beyond Monothera association”
BackgroundRassy, E., Dalban, C., Colomba, É., Derosa, L., Silva, C. A. C., Négrier, S., Chevreau, C., Gravis, G., Oudard, S. M., Laguerre, B., et al. (2022) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2022.07.003 · Cited by 20
Pérez-Ruiz, E., Jiménez-Castro, J., Berciano‐Guerrero, M., Valdivia, J., Estalella-Mendoza, S., Toscano, F., Artacho, M. R. D. L. B., Garrido-Siles, M., Bautista, M. J. M., Roldán, R. V., et al. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02315-9 · Cited by 20 · cited 2×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma
Homicskó, K., Dummer, R., Höeller, C., Wolchok, J. D., Hodi, F. S., Larkin, J., Ascierto, P. A., Atkinson, V. G., Robert, C., Postow, M. A., et al. (2022) · Cancers · doi:10.3390/cancers14092300 · Cited by 20 · cited 2×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
BackgroundKulkarni, A. A., Kumar, M., Pease, D. F., Wang, Y., DeFor, T. E., & Patel, M. R. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.e20520 · Cited by 20 · cited 2×
“Kulkarni (38) 2019 203 Europe NA NA NA Multiple Anti-PD-1, anti-PD-L1 NA NA”
BackgroundKunimitsu, Y., Morio, K., Hirata, S., Yamamoto, K., Omura, T., Hara, T., Harada, K., Fujisawa, M., & Yano, I. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00939 · Cited by 19 · cited 2×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
BackgroundAfzal, M. Z., & Shirai, K. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.e21040 · Cited by 17 · cited 3×
“Afzal (17) 2019 120 America NA 65 NA Melanoma Pembrolizumab, nivolumab, ipilimumab NA M as”
BackgroundTakada, K., Shimokawa, M., Takamori, S., Shimamatsu, S., Hirai, F., Ono, Y., Tagawa, T., Okamoto, T., Hamatake, M., Okamoto, I., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263247 · Cited by 14 · cited 2×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
Nguyen, Q. P., Nomura, M., Matsumoto, S., & Muto, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz338.107 · Cited by 12 · cited 2×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
BackgroundHusain, M., Xu, M., Patel, S. H., Johns, A. C., Grogan, M. M., Li, M., Lopez, G., Miah, A., Hoyd, R., Liu, Y., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.2633 · Cited by 11
Kfoury, M., Disdero, V., Vicier, C., Saux, O. L., Gougis, P., Sajous, C., & Vignot, S. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.04.011 · Cited by 8
Stokes, W. A., Behera, M., Jiang, R., Gutman, D. A., Giuste, F., Burns, A., Sebastian, N., Ramalingam, S. S., Sukhatme, V. V., Lowe, M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.e18729 · Cited by 7 · cited 2×
“Stokes (51) 2021 3,634 America 3,525 (97) 69 NA NSCLC”
Araújo, H. A., Moniz, C. M. V., Braghiroli, O. F. M., Mak, M. P., Uratani, L. F., Tiecher, R. D., Moraes, P. M., Barbosa, I., de Camargo, V. P., Braghiroli, M. I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.2652 · Cited by 7 · cited 2×
“Finally, 41 publications were eligible and were included in the meta-analysis (17, 18, 19; 20, 21, 10, 22-25, 26; 27-38, 39; 40-43, 44; 45-55, 13).”
BackgroundSurprescription des inhibiteurs de la pompe à protons
Esteves, M., Rollason, V., & Grosgurin, O. (2017) · JMIG · doi:10.53738/revmed.2017.13.579.1782 · Cited by 6
Valette, S., Dory, A., Gourieux, B., & Weber, J. (2020) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2020.11.014 · Cited by 5 · cited 1×
“PPI deprescription should be conducted whenever possible, following deprescribing protocols (86, 87).”
BackgroundSelf-citation[Proton pump inhibitors overprescription].
Esteves, M., Rollason, V., & Grosgurin, O. (2017) · PubMed · Cited by 3
Castro‐Balado, A., Lores, M. T., Sánchez, R. Á., Ferrán, B. B., Montero, E. L., Torre, A. M., Molino, B. M. P. D., & Ferro, I. Z. (2021) · Section 4: Clinical pharmacy services · doi:10.1136/ejhpharm-2021-eahpconf.133 · Cited by 3 · cited 2×
“Median age ECOG PS 0- 1/2 Cancer type ICI treatment Treatment line IC a Afzal (17) 2019 120 America NA 65 NA Melanoma Pembrolizumab, nivolumab, ipilimumab NA M as Araujo (18) 2021 216 America NA 59 199/17 Multiple Anti PD1, anti PD-L1 NA N Baeck (19) 2022 1,646 Asia 1,323 (80) 66 NA NSCLC Pembrolizumab, nivolumab, ate…”
Research works printed but not linked: 2
- 16. Wells GA Shea B O’connell D Peterson J Welch V Losos M. The Newcastle-Ottawa scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. (2009).
- 33. Hossain T Htut S and Pathmanathan S. Immunotherapy efficacy and concomitant proton pump inhibitor use in non-small cell lung cancer. Asia Pac J Clin Oncol (2020) 16: 37.
Cited by
Sawaid, I. O., & Samson, A. O. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13071970 · Cited by 48
“Conversely, PPI concomitant treatment also leads to significantly worse outcomes in advanced cancer patients [42], increases mortality risk [43], increases risk of disease progression [44] {, and reduces overall survival [45].”
BackgroundPharmacomicrobiomics: The Role of the Gut Microbiome in Immunomodulation and Cancer Therapy
Bolte, L. A., Björk, J. R., Gaćeša, R., & Weersma, R. K. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.04.025 · Cited by 43
Elkrief, A., Routy, B., Derosa, L., Bolte, L. A., Wargo, J. A., McQuade, J. L., & Zitvogel, L. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-472902 · Cited by 43
Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the ugly
Adashek, J. J., Moran, J. A., Le, D. T., & Kurzrock, R. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10260-8 · Cited by 37
“It has also been reported that the use of proton pump inhibitors or angiotensin-converting enzyme inhibitors correlates with worse survival in patients receiving ICIs [49, 50].”
Gut–lung axis: role of the gut microbiota in non-small cell lung cancer immunotherapy
Zhang, H., & Xu, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1257515 · Cited by 34
Metadata
- Authors
- Lopes, S., Pabst, L., Dory, A., Klotz, M., Gourieux, B., Michel, B., & Mascaux, C.
- Affiliations
- Hôpitaux Universitaires de Strasbourg (FR)
- Inserm (FR)
- Corresponding author
- Mascaux, Céline
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2023-01-26
- Volume
- 14
- Pages
- 1070076-1070076
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC9910608
- OpenAlex
- W4318049653
- Cited by
- 75
- References
- 85
- Citations by year
- 2026: 28 · 2025: 24 · 2024: 14 · 2023: 9
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- proton pump inhibitors, immune checkpoint inhibitors, gut microbiota, cancer immunotherapy, overall survival, progression-free survival, non-small cell lung cancer, urothelial carcinoma, anti-PD-1 therapy, PD-L1 blockade, antibiotic use, drug-drug interactions
- MeSH terms
- Immune Checkpoint Inhibitors, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Proton Pump Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.